Track Capricor Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Capricor Therapeutics, Inc. CAPR · Stock Open Capricor Therapeutics, Inc. in new tab

9.53 USD
EPS
-2.65
P/B
2.11
ROE
-73.70
Beta
0.77
Target Price
27.00 USD
Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

🧾 Earnings Recap – Q3 2026

Capricorn Therapeutics shares rose 26.5% after the earnings call, as investors responded to the company’s account of positive HOPE-3 efficacy data and its view that the FDA review is nearing completion. The BLA remains under review, with the agency’s target action date extended to November 22.

  • Capricorn said HOPE-3 met its primary endpoint: the 1-year difference on the Performance of the Upper Limb 2.0 was 1.1 points versus placebo (p=0.029), which management characterized as clinically meaningful.
  • In the 24-month open-label extension, patients who switched from placebo to deramiocel saw their annual decline slow from about 2 points to about 0.5 points; the company described these results as supportive but noted they are descriptive.
  • Cardiac results were mixed: deramiocel slowed progression of heart muscle scarring, while the overall ejection-fraction difference versus placebo was not statistically significant. In the prespecified subgroup with existing cardiomyopathy, ejection fraction improved by approximately 2.8 percentage points relative to placebo.
  • The FDA is reviewing an August BLA amendment that included 24-month HOPE-3 data and additional analyses. Capricorn said all requested information has been submitted; the review is ongoing.
  • Management said the proposed refined indication focuses on treatment of upper-limb impairment in patients older than 9 years.
📅
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
EPS-2.65
Book Value5.33
Price to Book2.11
Debt/Equity36.98
% Insiders9.437%
Estimates
Forward P/E-7.73
Forward EPS-1.45
Target Mean Price27.00

DCF valuation

Model fair value for Capricor Therapeutics, Inc. (CAPR)
Result
Sign in to run the valuation for CAPR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Buy · mean target 27.00 USD (low 7.00, high 54.00) · as of 12 Nov 2026
Low 7.00
Mean 27.00
High 54.00
Price 9.53
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Capricor Therapeutics, Inc. Logo Capricor Therapeutics, Inc. Analysis (CAPR)

United States Health Care Official Website Stock

Is Capricor Therapeutics, Inc. a good investment? Capricor Therapeutics, Inc. (CAPR) is currently trading at 9.53 USD. Market analysts have a consensus price target of 27.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Capricor Therapeutics, Inc. is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is -1.45.

Investor FAQ

Does Capricor Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Capricor Therapeutics, Inc.?

Capricor Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of -2.65.

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Exchange Ticker
FRA (Germany) 4LN2.F
NMS (United States) CAPR
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 21, 2013 1:50
June 5, 2019 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion